A Study to Identify the Risk of Non-alcoholic Fatty Liver Disease (NAFLD) in Patients With Type 2 Diabetes in Clinical Practice and to Evaluate the Clinical Usefulness of Dapagliflozin/Pioglitazone Combination Therapy

Boryung

Status: Enrolling

Conditions: Type 2 Diabetes

Study type: Observational

Funder types: Industry

Identifiers

NCT06649162

BR-DPC-OS-401

Details and patient eligibility

About

The purpose of this study is to identify the risk of non-alcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes in clinical practice and to evaluate the clinical usefulness of Dapagliflozin/Pioglitazone combination therapy

Enrollment: 10,000 estimated patients

Sex: All

Ages: 19+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Among patients with type 2 diabetes, those who are scheduled to administer a fixed-dose combination of dapagliflozin/pioglitazone at baseline (visit 1)
• Those who voluntarily signed a written personal information collection and usage agreement after listening to an explanation about the objective and method, etc. of this clinical study.

Exclusion criteria

• Those who have a history of taking a fixed-dose combination of dapagliflozin/pioglitazone at baseline (visit 1).
• Those who are expected to need insulin prescription during the study period.